This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma

This study has been completed.
Information provided by (Responsible Party):
Genentech, Inc. Identifier:
First received: October 20, 2010
Last updated: November 1, 2016
Last verified: November 2016
This is an open-label, multicenter, Phase I dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics (PK) of GDC-0917 in patients with refractory solid tumors or lymphoma.

Condition Intervention Phase
Solid Cancers Drug: GDC-0917 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered Daily in Patients With Refractory Solid Tumors or Lymphoma

Resource links provided by NLM:

Further study details as provided by Genentech, Inc.:

Primary Outcome Measures:
  • Changes in vital signs, ECGs, and clinical laboratory results [ Time Frame: Throughout study or until early discontinuation ]
  • Incidence and nature of dose-limiting toxicities and adverse events of special interest [ Time Frame: Throughout study or until early discontinuation ]
  • Incidence, nature, and severity of all adverse events and serious adverse events [ Time Frame: Throughout study or until early discontinuation ]

Secondary Outcome Measures:
  • Pharmacokinetic parameters of GDC-0917 (including total exposure, maximum and minimum serum concentration, time to maximum observed plasma concentration, elimination of half-life, accumulation at steady-state) [ Time Frame: Throughout study or until early discontinuation ]

Enrollment: 42
Study Start Date: October 2010
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: GDC-0917
Oral repeating dose


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically documented, locally advanced or metastatic solid tumors or lymphoma for which standard therapy either does not exist or has proven ineffective or intolerable
  • Life expectancy >/= 12 weeks
  • Adequate hematologic and end organ function
  • For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use an effective form of contraception and to continue its use for the duration of the study.

Exclusion Criteria:

  • Clinically significant history of chronic liver disease, active hepatic infection, evidence of hepatic cirrhosis or Grade >/= 2 liver dysfunction not due to hepatic metastases of cancer, current alcohol abuse, active infections with hepatitis B virus, or hepatitis C virus
  • Grade >/= 2 fever or associated constitutional symptoms, or a clinically significant systemic infection within the last month
  • Autoimmune disease
  • History of clinically significant pulmonary disease
  • Need for chronic and continuous systemic or topical corticosteroids or immunosuppressive therapy within 2 weeks prior to study entry or anticipated need of continuous systemic corticosteroids or immunosuppressive therapy during study participation.
  • Allergy or hypersensitivity to components of the GDC-0917 formulation
  • Palliative radiotherapy within 2 weeks prior to first dose of study drug treatment in Cycle 1
  • Experimental therapy within 4 weeks prior to first dose of study drug treatment in Cycle 1
  • Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study drug treatment in Cycle 1, or anticipation of the need for major surgery during the course of study treatment
  • Prior anti-cancer therapy within 4 weeks before the first dose of study drug treatment in Cycle 1
  • All acute drug-related toxicities must have resolved prior to study entry, except for alopecia and Grade 1 neuropathy
  • Current severe, uncontrolled systemic disease excluding cancer
  • History of clinically significant cardiac dysfunction
  • History of malabsorption or other condition that would interfere with enteral absorption
  • Any history of active GI bleeding within the past 6 months prior to screening
  • Known HIV infection
  • Uncontrolled ascites, due to diseases other than cancer, requiring weekly large-volume paracentesis for 3 consecutive weeks prior to enrollment
  • Pregnancy, lactation, breastfeeding or unwillingness to use birth control during the study and for 3 months after the last dose of GDC-0917
  • Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01226277

United States, Tennessee
Nashville, Tennessee, United States, 37203
United States, Texas
San Antonio, Texas, United States, 98229
Sponsors and Collaborators
Genentech, Inc.
Study Director: Chia Portera, M.D., Ph.D. Genentech, Inc.
  More Information

Responsible Party: Genentech, Inc. Identifier: NCT01226277     History of Changes
Other Study ID Numbers: 4914g
GO01306 ( Other Identifier: Hoffmann-La Roche )
Study First Received: October 20, 2010
Last Updated: November 1, 2016 processed this record on August 17, 2017